While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue guidance for the full year 2022 to reflect third quarter business updates.
from RTT - Earnings https://ift.tt/n1DsHl3
via IFTTT
No comments:
Post a Comment